Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. A New Technique for Diabetic Foot Ulcers

    SBC: Noveratech LLC            Topic: 200

    ABSTRACT Diabetes is the leading cause of nontraumatic lower extremity amputations in the United States Diabetic foot ulcers DFUs are responsible for more hospitalizations than any other diabetic complications Currently even the best available treatments achieve only a healing rate for these wounds and this healing is often only temporary with a chance of recurring Our company has ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. A NOVEL NEUROPROTECTIVE THERAPY FOR ALZHEIMER'S DISEASE

    SBC: Klogene Therapeutics, Inc.            Topic: NIA

    DESCRIPTION provided by applicant Alzheimerandapos s disease AD is one of the most significant public health problems of the st century with the number of patients in the US estimated to grow from million to million by and an annual cost of care projected to reach $ trillion Current treatments for AD have limited effect for a short duration and only serve to alleviate sympto ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A pro resolution lipid mediator for treatment of rheumatoid arthritis

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NIAMS

    Radikal Therapeutics is developing the first therapeutic Resolvin molecule intended for the management of rheumatoid arthritis RA Resolvins are endogenous picomolar potent small molecules that activate a complex intracellular mechanism by which tissue inflammation is modulated and ultimately resolved Our technical approach is supported by research demonstrating the utility of our candidate the ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A Quantitative Systems Pharmacology Software Platform for Biologics reduce costs and accelerate development of innovative biotherapeutics

    SBC: Applied BioMath, LLC            Topic: 300

    DESCRIPTION provided by applicant Drug development is a very lengthy and expensive undertaking Failure rate for novel drugs exceeds Therefore successful drugs must cover the costs of these failures As such prescription drug prices have escalated at an alarming rate and show no signs of stopping The need for successful drugs to cover failures also means that pharmaceutical companies p ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. A Vector free Intracellular Delivery Platform for Drug Discovery

    SBC: SQZ BIOTECHNOLOGIES COMPANY            Topic: 300

    PROJECT SUMMARY The cost of new therapy discovery has continued to increase and is estimated to be near $ billion per compound Technological advances allowing for more effective screening could have an immense clinical benefit and reduce the cost of drug discovery Gains in efficiency for compound screening could come through direct introduction of drug candidates into cells development of be ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. A mechanism based computational tool to optimize pulmonary drug delivery

    SBC: CFD Research Corporation            Topic: 300

    DESCRIPTION provided by applicant Pulmonary drug delivery has emerged as a noninvasive alternative route for the treatment of lung diseases asthma COPD CF and lung cancer In order to obtain the desired level of effectiveness and safety of the inhaled drugs an appropriate deposition on the targeted region and subsequent absorption in the targeted region is vital Multiscale multidisciplin ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. An HIV Viral Load Assay for the Point Of Care

    SBC: DAKTARI DIAGNOSTICS, INC.            Topic: NIAID

    Project Summary HIV remains a global health crisis more than million people died from the disease in While there has been significant progress in the last ten years more than million people currently receive effective antiretroviral therapy ART worldwide our ability to monitor and provide high quality care to HIV AIDS patients is still limited in part by the available diagnostics ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. An Open Source Precision Medicine Platform for Cloud Operating Systems

    SBC: CUROVERSE, INC.            Topic: 400

    DESCRIPTION provided by applicant Rapid improvements in DNA sequencing and synthesis have the potential to usher in a new era of precision medicine To realize this vision however we must re imagine the computational and storage infrastructure used to manage and extract actionable results from the massive data sets made possible by widely available advances in DNA sequencing and synthetic bi ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Antibody targeting of ADAM for treatment of triple negative breast cancer

    SBC: Adecto Pharmaceuticals, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Antimicrobial Biodegradable Bone Graft for Craniofacial Maxillofacial Application

    SBC: N2 Biomedical, LLC            Topic: NIDCR

    Project Summary Magnesium Mg and its alloys have attracted increasing interest for use as biodegradable implants such as fixation devices for orthopedic and cranio maxillofacial surgeries due to their promising mechanical and biological properties as well as their ability to degrade and resorb in the body The overall aim of the Phase II program is to extend encouraging Phase I results in whi ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government